$GCTK News

Glucotrack, Inc. Announces Reverse Stock Split

Glucotrack’s Subsidiary Lōkahi Therapeutics Unveils Qare Comparative Health Platform For GLP-1 And Other Treatment Outcomes

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

What's Going On With GlucoTrack Shares On Thursday?

Glucotrack Stock Is Trending: Here's Why GCTK Jumped Over 80% After Hours

Glucotrack’s Lōkahi Therapeutics Announces University Of Alabama’s Culverhouse College Of Business Will Continue Its Participation In ai² Pipeline Division For Upcoming Academic Year

Glucotrack Announces $11.5 Million Financing

Glucotrack Secures $11.5M Convertible Note Financing

Glucotrack, Inc. Announces Reverse Stock Split

Glucotrack's Lōkahi Therapeutic Subsidiary Initiates Good Manufacturing Practice Production Campaign For LT-100

Glucotrack Regains Nasdaq Equity Compliance as Strategic Transformation Advances

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

Glucotrack Announces That Nasdaq Hearings Panel Has Granted The Company's Request For Continued Listing, Subject To Conditions

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

Glucotrack Announces $5.5 Million Financing

GlucoTrack (GCTK) Stock Surges Over 70% After Hours: Why is it Moving?

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

GlucoTrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To One

Glucotrack Has Been Granted U.S. Patent Number 12,129,085 Titled "Methods and systems for continuously monitoring the glucose level of a patient".

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing